Pirfenidone 801 MG tablet 90S
Ended Awarded Last action
- Contract number
- SPE2DR26FQGZ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,542
Award facts
- Contract value 100% obligated
- $1,541.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,541.52 to DMS Pharmaceutical Group Inc. for Pirfenidone 801 mg tablets (90-count supply) with an ultimate completion date of February 5, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables across multiple therapeutic categories. Under its PPV-G GEN V prime vendor contract—valued at $499,999,999 with a completion date of December 31, 2036—DMS Pharmaceutical Group is positioned to provide recurring pharmaceutical support to military healthcare operations globally, with this delivery order for Pirfenidone representing one of numerous orders fulfilling the specialized pharmaceutical requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FQGZ4?
SPE2DR26FQGZ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FQGZ4 worth?
The government has obligated $1,542 on SPE2DR26FQGZ4.
Is contract SPE2DR26FQGZ4 an order under another contract?
Yes. SPE2DR26FQGZ4 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGZ4 competed?
The extent of competition for SPE2DR26FQGZ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award